Last updated: 6 June 2024 at 4:46pm EST

Neil Mendoza Net Worth



Neil Mendoza biography

Neil F. J. Mendoza serves as Independent Director of the Company. In 1986, Mr. Mendoza is Provost of Oriel College, Oxford University. In 1986, Mr. Mendoza founded the custom marketing and publishing agency Forward, subsequently renamed Bookmark Content and Communications, a subsidiary of WPP plc. Mr. Mendoza is the chairman of Victoria Private Investment Office, a London-based investment advisory firm, which he joined in 2010. He received a M.A. in Geography from Oxford University.

What is the salary of Neil Mendoza?

As the Independent Director of MeiraGTx plc, the total compensation of Neil Mendoza at MeiraGTx plc is $455,133. There are 9 executives at MeiraGTx plc getting paid more, with Alexandria Forbes having the highest compensation of $8,480,260.



How old is Neil Mendoza?

Neil Mendoza is 60, he's been the Independent Director of MeiraGTx plc since 2015. There are 7 older and 10 younger executives at MeiraGTx plc. The oldest executive at MeiraGTx Holdings plc is Arnold Levine, 80, who is the Independent Director.

What's Neil Mendoza's mailing address?

Neil's mailing address filed with the SEC is 450 EAST 29TH STREET, 14TH FLOOR, NEW YORK, NY, 10016.

Insiders trading at MeiraGTx plc

Over the last 6 years, insiders at MeiraGTx plc have traded over $7,031,523 worth of MeiraGTx plc stock and bought 9,222,038 units worth $85,317,799 . The most active insiders traders include Advisors Llcperceptive Life..., Joel S Marcus, and Life Sciences Master Fund L.... On average, MeiraGTx plc executives and independent directors trade stock every 33 days with the average trade being worth of $672,044. The most recent stock trade was executed by Advisors Llcperceptive Life... on 12 August 2024, trading 1,250,000 units of MGTX stock currently worth $5,000,000.



What does MeiraGTx plc do?

meiragtx, a london and new york-based gene therapy company, is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. we are pioneering the use of gene therapy to treat devastating neurodegenerative diseases such as alzheimer’s disease (ad), parkinson’s disease (pd), and amyotrophic lateral sclerosis (als). we are developing innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration (amd). meiragtx is also establishing treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. our revolutionary gene regulation technologies promise to transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.



What does MeiraGTx plc's logo look like?

MeiraGTx Holdings plc logo

MeiraGTx plc executives and stock owners

MeiraGTx plc executives and other stock owners filed with the SEC include: